Post-traumatic headache: Pathophysiology and management - A review

Background Post-traumatic headache (PTH) is a common secondary headache due to traumatic brain injury. In the past, significant research has been conducted to understand the pathophysiology and treatment options for PTH. However, PTH still lacks evidence-based treatment, and most of the management depends on the primary phenotype observed in the patient. Objective The main objective of this review is to provide a single reference that covers the current understanding of the pathophysiology and the treatment options available for PTH. Methods A detailed literature search on PubMed was performed, and a narrative review was prepared. Results The pathophysiology of PTH is multifactorial. Acute PTH may be attributed to increased peripheral pain sensitization with impaired pain inhibiting pathways. Chronic or persistent PTH may be due to a chronic inflammatory response and peripheral as well as central sensitization. The mechanism responsible for the transition of acute to persistent PTH is unknown. The migraine-like phenotype is reported to be the most prevalent headache type seen in PTH. New targets for preventive treatment have been identified in recent years, such as neuropeptides like calcitonin-gene-related peptide (CGRP), nitric oxide, and glutamate. The preventive pharmacological and non-pharmacological strategies employed for migraine (e.g. anti-CGRP monoclonal antibodies, onabotulinumtoxinA, physical therapy, cognitive and behavioral treatment, and neurostimulation techniques) have shown in preliminary studies that they are potentially efficacious, but large, randomized, double blind, placebo controlled trials are needed to further establish these as treatment options for PTH. Conclusions The lack of evidence-based treatment for PTH has created a need for future large trials to confirm the safety and efficacy of the currently employed treatments.

[1]  J. McVige,et al.  Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Treatment of Patients With Concussion , 2021, Neurology.

[2]  R. Burch,et al.  The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice , 2021, Headache.

[3]  Joshua Kamins Models for Treating Post-traumatic Headache , 2021, Current Pain and Headache Reports.

[4]  M. Ashina,et al.  Post-traumatic headache attributed to traumatic brain injury: classification, clinical characteristics, and treatment , 2021, The Lancet Neurology.

[5]  A. Blumenfeld,et al.  Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review , 2021, Pain and Therapy.

[6]  Stefano Tamburin,et al.  An updated brief overview on post-traumatic headache and a systematic review of the non-pharmacological interventions for its management , 2021, Expert review of neurotherapeutics.

[7]  G. Serafini,et al.  Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine , 2020, Pain and Therapy.

[8]  D. Elashoff,et al.  Botulinum Toxin Type A for the Treatment of Post-traumatic Headache: A Randomized, Placebo-Controlled, Cross-over Study. , 2020, Military medicine.

[9]  N. Khalil,et al.  Erenumab and OnabotulinumtoxinA Combination Therapy for the Prevention of Intractable Chronic Migraine without Aura: A Retrospective Analysis , 2020, Journal of pain & palliative care pharmacotherapy.

[10]  M. Ashina,et al.  Hypersensitivity to Calcitonin Gene–Related Peptide in Post‐Traumatic Headache , 2020, Annals of neurology.

[11]  K. Sequeira,et al.  Use of CGRP receptor blocker erenumab in the management of post-traumatic headache: a case series of 5 women , 2020, Brain injury.

[12]  R. Nonis,et al.  Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. , 2020, Revue neurologique (Paris).

[13]  M. Brin,et al.  Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review , 2020, Headache.

[14]  G. Serafini,et al.  The Relation between Persistent Post-Traumatic Headache and PTSD: Similarities and Possible Differences , 2020, International journal of environmental research and public health.

[15]  P. Martelletti,et al.  Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence , 2020, The Journal of Headache and Pain.

[16]  R. Burstein,et al.  Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale? , 2020, Headache.

[17]  M. Ashina,et al.  Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study , 2020, The Journal of Headache and Pain.

[18]  P. Azouvi,et al.  Definition and epidemiology of mild traumatic brain injury. , 2020, Neuro-Chirurgie.

[19]  M. Ashina,et al.  Risk Factors for the Development of Post‐Traumatic Headache Attributed to Traumatic Brain Injury: A Systematic Review , 2020, Headache.

[20]  P. Martelletti,et al.  Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons , 2020, International journal of environmental research and public health.

[21]  T. L. Chan,et al.  Exploring naturally occurring clinical subgroups of post-traumatic headache , 2020, The Journal of Headache and Pain.

[22]  M. Ashina,et al.  Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review , 2019, The Journal of Headache and Pain.

[23]  O. Monchi,et al.  Treatment of persistent post-traumatic headache and post-concussion symptoms using rTMS: a pilot, double-blind, randomized controlled trial. , 2019, Journal of neurotrauma.

[24]  T. Anderson,et al.  Post-traumatic headache: epidemiology and pathophysiological insights , 2019, Nature Reviews Neurology.

[25]  H. Diener,et al.  Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial , 2019, The Lancet.

[26]  A. Maassenvandenbrink,et al.  The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse , 2019, The journal of headache and pain.

[27]  M. Ashina,et al.  CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data , 2019, Cephalalgia : an international journal of headache.

[28]  L. Rapport,et al.  Outcomes after Concussion Recovery Education: Effects of Litigation and Disability Status on Maintenance of Symptoms. , 2019, Journal of neurotrauma.

[29]  S. Tepper,et al.  Effects of onabotulinumtoxinA treatment for chronic migraine on common comorbidities including depression and anxiety , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[30]  J. A. Charles Treatment of posttraumatic headache migraine phenotype with erenumab – An observational study , 2019, Journal of Concussion.

[31]  N. Silverberg Behavioral treatment for post-traumatic headache after mild traumatic brain injury: Rationale and case series. , 2019, NeuroRehabilitation.

[32]  A. G. Martin,et al.  Prevalence of Postconcussion Syndrome after Mild Traumatic Brain Injury in Young Adults from a Single Neurosurgical Center in East Coast of Malaysia , 2019, Asian journal of neurosurgery.

[33]  J. Dagher,et al.  Narrative Review of the Pathophysiology of Headaches and Photosensitivity in Mild Traumatic Brain Injury and Concussion , 2018, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[34]  A. Charles,et al.  Posttraumatic Headache: Basic Mechanisms and Therapeutic Targets , 2018, Headache.

[35]  M. Collins,et al.  Family History of Migraine Associated With Posttraumatic Migraine Symptoms Following Sport-Related Concussion , 2017, The Journal of head trauma rehabilitation.

[36]  Visar Berisha,et al.  Persistent post-traumatic headache vs. migraine: an MRI study demonstrating differences in brain structure , 2017, The Journal of Headache and Pain.

[37]  A. Belli,et al.  Disability from posttraumatic headache is compounded by coexisting posttraumatic stress disorder , 2017, Journal of pain research.

[38]  G. Hageman,et al.  Risk factors and outcomes associated with post-traumatic headache after mild traumatic brain injury , 2017, Emergency Medicine Journal.

[39]  M. Minen,et al.  Behavioral Treatments for Post-Traumatic Headache , 2017, Current Pain and Headache Reports.

[40]  K. Mautner,et al.  Sphenopalatine Ganglion Block for Management of Refractory Chronic Posttraumatic Headaches After a Sport-Related Concussion , 2017, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[41]  D. Dodick,et al.  Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis , 2016, Cephalalgia : an international journal of headache.

[42]  D. Meldrum,et al.  Can vestibular rehabilitation exercises help patients with concussion? A systematic review of efficacy, prescription and progression patterns , 2016, British Journal of Sports Medicine.

[43]  M. Choe The Pathophysiology of Concussion , 2016, Current Pain and Headache Reports.

[44]  F. Conidi Interventional Treatment for Post-traumatic Headache , 2016, Current Pain and Headache Reports.

[45]  R. Jensen Pharmacological Treatment of Acute and Chronic Post-traumatic Headache , 2016 .

[46]  K. Barlow,et al.  Occipital Nerve Blocks for Pediatric Posttraumatic Headache , 2015, Journal of child neurology.

[47]  Vittal R. Nagar,et al.  Systematic review of radiofrequency ablation and pulsed radiofrequency for management of cervicogenic headache. , 2015, Pain physician.

[48]  Marina A. Khusid Clinical indications for acupuncture in chronic post-traumatic headache management. , 2015, Military medicine.

[49]  R. Cady,et al.  A Double-Blind, Placebo-Controlled Study of Repetitive Transnasal Sphenopalatine Ganglion Blockade With Tx360® as Acute Treatment for Chronic Migraine , 2014, Headache.

[50]  Carrie E. Robertson,et al.  Trigger Point Injections for Headache Disorders: Expert Consensus Methodology and Narrative Review , 2014, Headache.

[51]  Dajie Wang,et al.  Treatment of Cervicogenic Headache with Cervical Epidural Steroid Injection , 2014, Current Pain and Headache Reports.

[52]  K. Barlow,et al.  Cervicovestibular rehabilitation in sport-related concussion: a randomised controlled trial , 2014, British Journal of Sports Medicine.

[53]  D. Friedman,et al.  Pediatric Post‐Traumatic Headaches and Peripheral Nerve Blocks of the Scalp: A Case Series and Patient Satisfaction Survey , 2014, Headache.

[54]  S. Dikmen,et al.  A prospective study of prevalence and characterization of headache following mild traumatic brain injury , 2014, Cephalalgia : an international journal of headache.

[55]  R. Defrin Chronic post-traumatic headache: clinical findings and possible mechanisms , 2014, The Journal of manual & manipulative therapy.

[56]  L. Balcer,et al.  Concussion , 2014, Annals of Internal Medicine.

[57]  Al-Sayed A. Shanb,et al.  Mobilization versus massage therapy in the treatment of cervicogenic headache: a clinical study. , 2013, Journal of back and musculoskeletal rehabilitation.

[58]  J. Silver Effort, exaggeration and malingering after concussion , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[59]  T. Wilt,et al.  Multidisciplinary Postacute Rehabilitation for Moderate to Severe Traumatic Brain Injury in Adults , 2012 .

[60]  S. Dikmen,et al.  Characterization of headache after traumatic brain injury , 2012, Cephalalgia : an international journal of headache.

[61]  J. Leddy,et al.  Rehabilitation of Concussion and Post-concussion Syndrome , 2012, Sports health.

[62]  S. Lucas Headache Management in Concussion and Mild Traumatic Brain Injury , 2011, PM & R : the journal of injury, function, and rehabilitation.

[63]  Allen W. Brown,et al.  Natural history of headache after traumatic brain injury. , 2011, Journal of neurotrauma.

[64]  S. Silberstein,et al.  Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well‐Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program , 2010, Headache.

[65]  H. Diener,et al.  OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial , 2010, Cephalalgia : an international journal of headache.

[66]  R. Evans,et al.  Posttraumatic Headache: A Review , 2010, Current pain and headache reports.

[67]  Valdenilson Ribeiro Ribas,et al.  Post-traumatic headache. , 2009, Arquivos de neuro-psiquiatria.

[68]  K. Guskiewicz,et al.  Balance deficits after sports-related concussion in individuals reporting posttraumatic headache. , 2008, Neurosurgery.

[69]  S. Silberstein,et al.  Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[70]  C. Paniak,et al.  Litigation and persistent post-concussion syndrome (PPCS) , 1999 .